Get the Stockscreener App
24.01
3.27%
0.76
After Hours:
24.24
0.23
+0.96%
Sarepta Therapeutics Inc stock is traded at $24.01, with a volume of 4.49M.
It is up +3.27% in the last 24 hours and up +24.60% over the past month.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
See More
Previous Close:
$23.25
Open:
$23.42
24h Volume:
4.49M
Relative Volume:
0.62
Market Cap:
$2.35B
Revenue:
$2.48B
Net Income/Loss:
$-57.96M
P/E Ratio:
-31.65
EPS:
-0.7585
Net Cash Flow:
$-453.97M
1W Performance:
+5.26%
1M Performance:
+24.60%
6M Performance:
-61.52%
1Y Performance:
-80.94%
1-Day Range:
$23.02
$24.48
1-Week Range:
$22.79
$24.48
52-Week Range:
$10.41
$138.81
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
24.01 | 2.43B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-29-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-25 | Initiated | Bernstein | Mkt Perform |
| Jul-29-25 | Reiterated | H.C. Wainwright | Sell |
| Jul-29-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Jul-29-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-28-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Jul-25-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-25 | Initiated | Citigroup | Sell |
| Jul-23-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-22-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-21-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-21-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jul-21-25 | Downgrade | Needham | Hold → Underperform |
| Jul-21-25 | Downgrade | UBS | Buy → Neutral |
| Jul-18-25 | Downgrade | Needham | Buy → Hold |
| Jun-20-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-25 | Downgrade | TD Cowen | Buy → Hold |
| Jun-17-25 | Initiated | Wolfe Research | Peer Perform |
| Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
| Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
When is the best time to exit Sarepta Therapeutics Inc.Earnings Overview Summary & Low Volatility Stock Suggestions - newser.com
Relative strength of Sarepta Therapeutics Inc. in sector analysisWeekly Trade Analysis & Low Risk High Reward Trade Ideas - newser.com
Is Sarepta Therapeutics Inc. trending in predictive chart models2025 Market Trends & Growth Focused Stock Pick Reports - newser.com
How Sarepta Therapeutics Inc. (AB3A) stock expands through international marketsShare Buyback & Free Reliable Trade Execution Plans - newser.com
Analyzing drawdowns of Sarepta Therapeutics Inc. with statistical tools2025 Investor Takeaways & Stock Portfolio Risk Management - newser.com
Combining machine learning predictions for Sarepta Therapeutics Inc.Earnings Risk Report & Advanced Technical Signal Analysis - newser.com
Is Sarepta Therapeutics Inc. (AB3A) stock testing key supportJuly 2025 Spike Watch & Growth Focused Investment Plans - newser.com
What technical charts say about Sarepta Therapeutics Inc. stock2025 Year in Review & Verified Stock Trade Ideas - newser.com
What market sentiment indicators show for Sarepta Therapeutics Inc. (AB3A) stockJuly 2025 PostEarnings & Free Real-Time Volume Trigger Notifications - newser.com
SAREPTA THERAPEUTICS Earnings Preview: Recent $SRPT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Can Sarepta Therapeutics Inc. (AB3A) stock attract analyst upgradesQuarterly Portfolio Review & Free Safe Entry Trade Signal Reports - newser.com
Is Sarepta Therapeutics Inc. stock supported by strong cash flows2025 Big Picture & Advanced Swing Trade Entry Plans - newser.com
What makes Sarepta Therapeutics Inc. (AB3A) stock appealing to growth investorsBear Alert & Weekly High Potential Stock Alerts - newser.com
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $16.00 - MarketBeat
Is Sarepta Therapeutics Inc. stock attractive for passive investors2025 Buyback Activity & Daily Profit Maximizing Trade Tips - newser.com
What to do if you’re stuck in Sarepta Therapeutics Inc.Volume Spike & Free Risk Controlled Daily Trade Plans - newser.com
Is Sarepta Therapeutics Inc. stock ready for a breakoutJuly 2025 Trends & Weekly Setup with ROI Potential - newser.com
Is Sarepta Therapeutics Inc. stock a good choice for value investors2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
How Sarepta Therapeutics Inc. stock benefits from global expansion2025 Major Catalysts & AI Powered Buy/Sell Recommendations - newser.com
Will Sarepta Therapeutics Inc. stock benefit from sector rotationJuly 2025 PreEarnings & Reliable Intraday Trade Alerts - newser.com
Sarepta Therapeutics’ Long-term Study on SRP-9001: A Boost for Investor Confidence? - TipRanks
Will breakout in Sarepta Therapeutics Inc. lead to full recoveryWeekly Risk Report & Community Consensus Trade Signals - newser.com
How to escape a deep drawdown in Sarepta Therapeutics Inc.2025 Winners & Losers & AI Driven Stock Reports - newser.com
Sarepta’s Gene Therapy Study: A Potential Game-Changer for Duchenne Muscular Dystrophy - TipRanks
Piper Sandler Maintains Sarepta Therapeutics (SRPT) Neutral Recommendation - Nasdaq
Interesting SRPT Put And Call Options For December 19th - Nasdaq
Piper Sandler Maintains Neutral Rating on SRPT, Raises Price Tar - GuruFocus
Sarepta Therapeutics (SRPT) to Release Quarterly Earnings on Monday - MarketBeat
Allianz Asset Management GmbH Has $252,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Can Sarepta Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Market Summary & Real-Time Buy Zone Alerts - fcp.pa.gov.br
Will Sarepta Therapeutics Inc. stock keep outperforming rivalsJuly 2025 Technicals & Free Weekly Watchlist of Top Performers - fcp.pa.gov.br
Using Bollinger Bands to evaluate Sarepta Therapeutics Inc.Quarterly Portfolio Review & Entry Point Confirmation Signals - newser.com
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Hold" by Analysts - MarketBeat
Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results - BioSpace
Is Sarepta Therapeutics Inc. stock trading near support levels2025 Market Trends & Free Expert Verified Stock Movement Alerts - fcp.pa.gov.br
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):